SG11201908051RA - Modified human igm constant regions for modulation of complement-dependent cytolysis effector function - Google Patents
Modified human igm constant regions for modulation of complement-dependent cytolysis effector functionInfo
- Publication number
- SG11201908051RA SG11201908051RA SG11201908051RA SG11201908051RA SG11201908051RA SG 11201908051R A SG11201908051R A SG 11201908051RA SG 11201908051R A SG11201908051R A SG 11201908051RA SG 11201908051R A SG11201908051R A SG 11201908051RA SG 11201908051R A SG11201908051R A SG 11201908051RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- complement
- modulation
- pct
- constant regions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Prostheses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
N O N N co (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO PCT omit VIII °nolo OH mo molionflou (10) International Publication Number WO 2018/187702 A2 (51) International Patent Classification: C12Q 1/68 (2018.01) (21) International Application Number: PCT/US2018/026474 (22) International Filing Date: 06 April 2018 (06.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/483,087 07 April 2017 (07.04.2017) US (71) Applicant: IGM BIOSCIENCES A/S [DK/US]; Haldor Topsoes All& 1, 2800 Kgs. Lyngby (DK). (72) Inventors: BALIGA, Ramesh; 2237 Hopkins Avenue, Redwood City, California 94062 (US). NG, Dean; 3966 18th Street, San Francisco, California 94114 (US). (74) Agent: HAANES, Elizabeth J.; FisherBroyles LLP, 945 East Paces Ferry Road N.E., Suite 2000, Atlanta, GA 30328 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with declaration under Article 17(2)(a); without abstract; title not checked by the International Searching Authority 1-1 (54) Title: MODIFIED HUMAN IGM CONSTANT REGIONS FOR MODULATION OF COMPLEMENT-DEPENDENT CY- TOLYSIS EFFECTOR FUNCTION 0 (57) :
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483087P | 2017-04-07 | 2017-04-07 | |
| PCT/US2018/026474 WO2018187702A2 (en) | 2017-04-07 | 2018-04-06 | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908051RA true SG11201908051RA (en) | 2019-09-27 |
Family
ID=63713537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908051RA SG11201908051RA (en) | 2017-04-07 | 2018-04-06 | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11401337B2 (en) |
| EP (1) | EP3607091A4 (en) |
| JP (2) | JP2020512820A (en) |
| KR (1) | KR102696143B1 (en) |
| CN (1) | CN110536900B (en) |
| AU (1) | AU2018248336B2 (en) |
| CA (1) | CA3055790A1 (en) |
| IL (1) | IL268901A (en) |
| MX (1) | MX2019011986A (en) |
| SG (1) | SG11201908051RA (en) |
| WO (1) | WO2018187702A2 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016018313A8 (en) | 2014-02-10 | 2018-06-12 | Igm Biosciences Inc | IGA MULTI-SPECIFIC BINDING MOLECULES |
| KR102380402B1 (en) | 2014-04-03 | 2022-03-31 | 아이쥐엠 바이오사이언스 인코포레이티드 | Modified j-chain |
| SG10202001779UA (en) | 2015-01-20 | 2020-04-29 | Igm Biosciences Inc | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
| DK3265575T3 (en) | 2015-03-04 | 2021-05-31 | Igm Biosciences Inc | CD20 BINDING MOLECULES AND USES THEREOF |
| CN107921285B (en) | 2015-03-25 | 2022-06-07 | Igm生物科学股份有限公司 | Multivalent hepatitis b virus antigen binding molecules and uses thereof |
| WO2016168758A1 (en) | 2015-04-17 | 2016-10-20 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| JP7065766B2 (en) | 2015-09-30 | 2022-05-12 | アイジーエム バイオサイエンシズ インコーポレイテッド | Bonded molecule with modified J chain |
| HUE055972T2 (en) | 2016-05-09 | 2022-01-28 | Igm Biosciences Inc | Anti-pd-l1 antibodies |
| US11401337B2 (en) * | 2017-04-07 | 2022-08-02 | Igm Biosciences, Inc. | Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function |
| CN111787951A (en) | 2018-03-01 | 2020-10-16 | Igm生物科学股份有限公司 | IgM Fc and J chain mutations affecting IgM serum half-life |
| CA3113268A1 (en) * | 2018-10-23 | 2020-04-30 | Igm Biosciences, Inc. | Multivalent igm- and iga-fc-based binding molecules |
| MX2022001934A (en) | 2019-08-15 | 2022-03-11 | Igm Biosciences Inc | Immunostimulatory multimeric binding molecules. |
| IL297029A (en) | 2020-04-22 | 2022-12-01 | Igm Biosciences Inc | Pd-1 agonist multimeric binding molecules |
| AU2023216348A1 (en) * | 2022-02-03 | 2024-06-20 | Igm Biosciences, Inc. | Anti-cd38 binding molecules and uses thereof |
| AU2023249803A1 (en) | 2022-04-07 | 2024-11-07 | Repertoire Immune Medicines, Inc. | T cell receptor multimers and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256771A (en) | 1990-04-03 | 1993-10-26 | Miles Inc. | Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| US20050014932A1 (en) | 2003-05-15 | 2005-01-20 | Iogenetics, Llc | Targeted biocides |
| US20150071948A1 (en) * | 2003-09-26 | 2015-03-12 | Gregory Alan Lazar | Novel immunoglobulin variants |
| KR101200188B1 (en) * | 2003-12-25 | 2012-11-13 | 교와 핫꼬 기린 가부시키가이샤 | Mutants of anti-cd40 antibody |
| US8377435B2 (en) | 2004-11-05 | 2013-02-19 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody induced cell membrane wounding |
| JP6007420B2 (en) * | 2009-11-04 | 2016-10-12 | ファブラス エルエルシー | Antibody optimization method based on affinity maturation |
| CA2849765C (en) * | 2011-09-26 | 2021-10-19 | Jn Biosciences Llc | Hybrid constant regions |
| US9409976B2 (en) | 2012-02-08 | 2016-08-09 | Igm Biosciences, Inc. | CDIM binding proteins and uses thereof |
| EP3041862B1 (en) | 2013-09-05 | 2020-05-06 | IGM Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
| US9416496B2 (en) * | 2013-10-16 | 2016-08-16 | Georgia-Pacific Consumer Products Lp | Method for reducing the bulk and increasing the density of a tissue product |
| BR112016018313A8 (en) | 2014-02-10 | 2018-06-12 | Igm Biosciences Inc | IGA MULTI-SPECIFIC BINDING MOLECULES |
| JP6512214B2 (en) * | 2014-02-25 | 2019-05-15 | 富士レビオ株式会社 | Modified monomer IgM |
| KR102380402B1 (en) | 2014-04-03 | 2022-03-31 | 아이쥐엠 바이오사이언스 인코포레이티드 | Modified j-chain |
| SG10202001779UA (en) | 2015-01-20 | 2020-04-29 | Igm Biosciences Inc | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
| DK3265575T3 (en) | 2015-03-04 | 2021-05-31 | Igm Biosciences Inc | CD20 BINDING MOLECULES AND USES THEREOF |
| CN107921285B (en) | 2015-03-25 | 2022-06-07 | Igm生物科学股份有限公司 | Multivalent hepatitis b virus antigen binding molecules and uses thereof |
| WO2016168758A1 (en) | 2015-04-17 | 2016-10-20 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| WO2017053469A2 (en) * | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| JP7065766B2 (en) | 2015-09-30 | 2022-05-12 | アイジーエム バイオサイエンシズ インコーポレイテッド | Bonded molecule with modified J chain |
| CN105441455B (en) * | 2015-10-21 | 2020-08-28 | 重庆金迈博生物科技有限公司 | Chimeric nucleic acid molecule and application thereof in preparation of humanized antibody |
| HUE055972T2 (en) | 2016-05-09 | 2022-01-28 | Igm Biosciences Inc | Anti-pd-l1 antibodies |
| JP2019530640A (en) | 2016-07-20 | 2019-10-24 | アイジーエム バイオサイエンシズ インコーポレイテッド | Multimeric OX40 binding molecule and use thereof |
| US20190330360A1 (en) | 2016-07-20 | 2019-10-31 | Igm Biosciences, Inc. | Multimeric gitr binding molecules and uses thereof |
| AU2017299610B2 (en) | 2016-07-20 | 2022-09-29 | Igm Biosciences, Inc. | Multimeric CD40 binding molecules and uses thereof |
| EP3487298A4 (en) | 2016-07-20 | 2020-03-11 | IGM Biosciences, Inc. | Multimeric cd137/4-1bb binding molecules and uses thereof |
| US11401337B2 (en) * | 2017-04-07 | 2022-08-02 | Igm Biosciences, Inc. | Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function |
| AU2019224136A1 (en) | 2018-02-26 | 2020-09-10 | Igm Biosciences, Inc. | Use of a multimeric anti-DR5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
| CN111787951A (en) | 2018-03-01 | 2020-10-16 | Igm生物科学股份有限公司 | IgM Fc and J chain mutations affecting IgM serum half-life |
| CA3113268A1 (en) | 2018-10-23 | 2020-04-30 | Igm Biosciences, Inc. | Multivalent igm- and iga-fc-based binding molecules |
-
2018
- 2018-04-06 US US16/500,292 patent/US11401337B2/en active Active
- 2018-04-06 JP JP2019554816A patent/JP2020512820A/en active Pending
- 2018-04-06 AU AU2018248336A patent/AU2018248336B2/en active Active
- 2018-04-06 CA CA3055790A patent/CA3055790A1/en active Pending
- 2018-04-06 CN CN201880022469.1A patent/CN110536900B/en active Active
- 2018-04-06 MX MX2019011986A patent/MX2019011986A/en unknown
- 2018-04-06 SG SG11201908051RA patent/SG11201908051RA/en unknown
- 2018-04-06 WO PCT/US2018/026474 patent/WO2018187702A2/en active Application Filing
- 2018-04-06 KR KR1020197030684A patent/KR102696143B1/en active IP Right Grant
- 2018-04-06 EP EP18781914.9A patent/EP3607091A4/en active Pending
-
2019
- 2019-08-25 IL IL26890119A patent/IL268901A/en unknown
-
2022
- 2022-06-10 US US17/806,339 patent/US20220340676A1/en active Pending
-
2023
- 2023-04-07 JP JP2023062508A patent/JP2023085503A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018187702A2 (en) | 2018-10-11 |
| US20210147567A1 (en) | 2021-05-20 |
| KR20190137821A (en) | 2019-12-11 |
| JP2020512820A (en) | 2020-04-30 |
| EP3607091A2 (en) | 2020-02-12 |
| JP2023085503A (en) | 2023-06-20 |
| EP3607091A4 (en) | 2021-01-20 |
| KR102696143B1 (en) | 2024-08-21 |
| US11401337B2 (en) | 2022-08-02 |
| CN110536900B (en) | 2024-06-11 |
| CN110536900A (en) | 2019-12-03 |
| US20220340676A1 (en) | 2022-10-27 |
| IL268901A (en) | 2019-10-31 |
| CA3055790A1 (en) | 2018-10-11 |
| AU2018248336A1 (en) | 2019-09-26 |
| MX2019011986A (en) | 2019-11-07 |
| AU2018248336B2 (en) | 2024-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908051RA (en) | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function | |
| SG11201809336QA (en) | Anti-pd-l1 antibodies | |
| SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201807437XA (en) | Antibodies specific to human poliovirus receptor (pvr) | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201807401RA (en) | Therapeutic membrane vesicles | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201906552WA (en) | TGF-ß DECOY RECEPTOR | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201907948TA (en) | Formulations comprising pd-1 binding proteins and methods of making thereof | |
| SG11201909009TA (en) | Catheter securement device with window | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201908678XA (en) | Methods and compositions for reduction of immunogenicity | |
| SG11201908744PA (en) | Anti-c5a antibodies and uses thereof | |
| SG11201909466RA (en) | Human anti-semaphorin 4d antibody | |
| SG11201901597UA (en) | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof |